Your browser is no longer supported. Please, upgrade your browser.
Settings
AGE AgeX Therapeutics, Inc. daily Stock Chart
AGE [NYSE]
AgeX Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own44.01% Shs Outstand39.39M Perf Week-17.69%
Market Cap47.66M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float21.08M Perf Month-32.02%
Income-12.60M PEG- EPS next Q- Inst Own24.80% Short Float4.68% Perf Quarter-15.97%
Sales1.50M P/S31.77 EPS this Y-17.00% Inst Trans-1.60% Short Ratio10.00 Perf Half Y-54.51%
Book/sh0.12 P/B10.08 EPS next Y- ROA-121.90% Target Price- Perf Year-75.05%
Cash/sh0.10 P/C12.54 EPS next 5Y- ROE-181.40% 52W Range1.08 - 4.99 Perf YTD-33.52%
Dividend- P/FCF- EPS past 5Y- ROI-152.00% 52W High-75.75% Beta-
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin76.90% 52W Low12.02% ATR0.15
Employees12 Current Ratio1.60 Sales Q/Q0.00% Oper. Margin- RSI (14)35.04 Volatility11.98% 11.58%
OptionableNo Debt/Eq0.05 EPS Q/Q-42.50% Profit Margin- Rel Volume0.55 Prev Close1.26
ShortableYes LT Debt/Eq0.05 EarningsMar 30 AMC Payout- Avg Volume98.76K Price1.21
Recom- SMA20-12.76% SMA50-22.99% SMA200-46.07% Volume54,263 Change-3.97%
Feb-09-20 09:12AM  The AgeX Therapeutics (NYSEMKT:AGE) Share Price Is Down 65% So Some Shareholders Are Wishing They Sold Simply Wall St.
Feb-03-20 08:00AM  AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other Neurological Disorders Business Wire
Jan-29-20 08:00AM  AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells Business Wire -8.19%
Jan-14-20 08:00AM  AgeX Therapeutics to Participate at Four Conferences in January 2020 Business Wire +8.82%
Dec-26-19 08:00AM  AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd. Business Wire
Dec-10-19 08:00AM  Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells Business Wire -9.68%
08:00AM  AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells Business Wire
Dec-09-19 07:00AM  AgeX Therapeutics Issues Year-End Letter to Shareholders Business Wire +23.02%
Nov-14-19 04:00PM  AgeX Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-13-19 09:50AM  IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholder - WMGI, AXE, CISN ACCESSWIRE
Nov-11-19 05:28AM  What Kind Of Shareholder Owns Most AgeX Therapeutics, Inc. (NYSEMKT:AGE) Stock? Simply Wall St.
Nov-08-19 06:58PM  AgeX Therapeutics to Present at Investing in the Age of Longevity Conference Business Wire
Oct-30-19 08:00AM  AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyteTM Technology Platform Business Wire
Oct-11-19 08:00AM  AgeX Therapeutics to Present at Metabesity 2019 Business Wire
Sep-10-19 08:00AM  Industry Leaders Aubrey De Grey And Frank Jaksch Join Yuva Biosciences Advisory Board PR Newswire
Sep-09-19 07:00AM  AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference Business Wire
Sep-04-19 08:00AM  AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine Business Wire
Aug-14-19 05:16PM  AgeX Therapeutics, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire
Aug-05-19 05:14PM  Regenerative Medicine Leader Michael H. May Joins AgeX Board of Directors Business Wire
Jul-09-19 08:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research Business Wire -7.36%
May-15-19 04:05PM  AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire -5.20%
May-01-19 08:00AM  AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute Business Wire
Apr-05-19 08:00AM  AgeX Therapeutics to Present at Master Investor Show 2019 Business Wire +13.88%
Apr-01-19 04:48PM  AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update Business Wire
Mar-22-19 07:00AM  AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants Business Wire
Mar-21-19 07:00AM  AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany Business Wire
Mar-07-19 07:00AM  LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration Business Wire
Feb-14-19 08:00AM  BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias GlobeNewswire +5.37%
Jan-31-19 08:00AM  AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London Business Wire
Jan-22-19 08:00AM  AgeX Therapeutics CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019 Business Wire -10.40%
Jan-10-19 08:00AM  LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market Business Wire +21.61%
Jan-09-19 08:00AM  AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity Business Wire
Jan-04-19 08:00AM  BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase GlobeNewswire +13.83%
Jan-02-19 07:00AM  AgeX Therapeutics to Present at Biotech Showcase 2019 Business Wire
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of cellular and regenerative therapeutics for diseases of old age in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders. The company was founded in 2017 and is based in Alameda, California.